PressJanuary 10, 2023 Israel-Based Clearmind Medicine Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial
PressJanuary 10, 2023 Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation
PressJanuary 9, 2023 Reunion Neuroscience Inc. Completes Interim Data Analysis for Phase 1 Clinical Trial with Novel Serotonergic Psychedelic RE104
PressJanuary 9, 2023 First Patient Dosed in Small Pharma’s Phase I Study Exploring Intramuscular Administration of SPL026
PressJanuary 9, 2023 PharmaTher Announces FDA Orphan Drug Designation Granted to Ketamine for Prevention of Ischemia-Reperfusion Injury from Organ Transplantation
PressJanuary 9, 2023 GH Research Reports Third Quarter 2022 Financial Results and Provides Business Updates
PressJanuary 9, 2023 atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression
PressJanuary 9, 2023 MAPS PBC Announces Positive Results from Confirmatory Phase 3 “MAPP2” Trial of MDMA-Assisted Therapy for Treatment of PTSD
PressJanuary 5, 2023 Tryp Therapeutics Announces Interim Results for Its Phase II Clinical Trial for the Treatment of Binge Eating Disorder With Psilocybin-Assisted Psychotherapy
PressJanuary 5, 2023 PsyBio Announces Closing of First Tranche of Private Placement and Provides Corporate Update
PressJanuary 5, 2023 PsychedelicNewsBreaks – Universal Ibogaine Inc. Recaps 2022, Eyes 2023 as ‘Pivotal Year’
PressJanuary 5, 2023 Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
PressJanuary 5, 2023 Israel-Based Clearmind Medicine Shows Efficacy of Psychedelic- Derived Obesity Treatment in Pre-Clinical Trial
PressJanuary 5, 2023 SciSparc Ltd. Announces Efficacy of Psychedelic-Based Obesity Treatment of Clearmind Medicine Inc. in Pre-Clinical Trial
PressJanuary 5, 2023 Reset Pharmaceuticals Appoints Innes Meldrum as President and Chief Executive Officer
PressJanuary 3, 2023 Tryp Therapeutics and Massachusetts General Hospital Sign Letter of Intent for Clinical Study Investigating the Use of Psilocybin-Assisted Psychotherapy for the Treatment of Patients Suffering From Irritable Bowel Syndrome (IBS)
PressJanuary 3, 2023 Algernon Pharmaceuticals Forms Private Subsidiary to Advance Company’s Psychedelic DMT Stroke Program; Files Form 1-A Offering Statement with U.S. SEC for Regulation A+ Offering
